Greg Jennings LLC Builds Fresh Stake in Johnson & Johnson
Greg Jennings LLC opened a new Johnson & Johnson position in the third quarter, buying 13,337 shares valued at roughly $3.53 million. The holding represents about 2.4% of the firm’s assets and ranks as its 15th-largest investment. Johnson & Johnson beat quarterly EPS expectations, grew revenue 5.9% year over year, and declared a $1.34 quarterly dividend.
Greg Jennings LLC disclosed a new 13,337-share J&J stake worth about $3.53 million, or 2.4% of its assets and its 15th-largest holding. Other institutions also moved: Abel Hall and Crown Wealth each added 2.0%, James Hambro raised 51.3%, Washburn opened a $1.101 million position, and Prairie Advisory more than doubled its stake. Institutions own 69.55%.
Insiders sold 64,515 shares worth roughly $17.27 million in 90 days. EVP Timothy Schmid sold 33,597 at an average $274.74, cutting his direct stake 56.90%; EVP Jennifer Taubert sold 15,000 at $263.36, a 7.16% reduction. J&J beat EPS estimates, grew revenue 5.9%, and declared a $1.34 quarterly dividend.
The disclosure may matter mainly to investors and retirement savers exposed to J&J through funds, since institutional and insider activity can influence sentiment around a large health-care company. If the stock’s performance holds up, it could support portfolio values and dividend income for shareholders; weaker results or heavy insider selling may prompt caution. Employees, patients, and communities could feel indirect effects through company investment and pricing decisions, though this filing alone is unlikely to change those outcomes.